New registry tracks inflammatory breast cancer to uncover hidden disease clues

NCT ID NCT06966050

First seen Nov 06, 2025 · Last updated May 15, 2026 · Updated 21 times

Summary

This study is creating a registry of 200 people with stage III or IV inflammatory breast cancer (IBC) who have had a blood test called Signatera to look for leftover cancer cells (MRD). Researchers will collect medical data and quality-of-life survey results to better understand how the disease behaves and how it affects daily life. Participants must be within eight months of diagnosis and have not yet had breast surgery for this cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.